Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters
MK Lo, BH Bird, A Chattopadhyay, CP Drew, BE Martin… - Antiviral research, 2014 - Elsevier
MK Lo, BH Bird, A Chattopadhyay, CP Drew, BE Martin, JD Coleman, JK Rose, ST Nichol…
Antiviral research, 2014•ElsevierNipah virus (NiV) continues to cause outbreaks of fatal human encephalitis due to spillover
from its bat reservoir. We determined that a single dose of replication-defective vesicular
stomatitis virus (VSV)-based vaccine vectors expressing either the NiV fusion (F) or
attachment (G) glycoproteins protected hamsters from over 1000 times LD 50 NiV challenge.
This highly effective single-dose protection coupled with an enhanced safety profile makes
these candidates ideal for potential use in livestock and humans.
from its bat reservoir. We determined that a single dose of replication-defective vesicular
stomatitis virus (VSV)-based vaccine vectors expressing either the NiV fusion (F) or
attachment (G) glycoproteins protected hamsters from over 1000 times LD 50 NiV challenge.
This highly effective single-dose protection coupled with an enhanced safety profile makes
these candidates ideal for potential use in livestock and humans.
Abstract
Nipah virus (NiV) continues to cause outbreaks of fatal human encephalitis due to spillover from its bat reservoir. We determined that a single dose of replication-defective vesicular stomatitis virus (VSV)-based vaccine vectors expressing either the NiV fusion (F) or attachment (G) glycoproteins protected hamsters from over 1000 times LD50 NiV challenge. This highly effective single-dose protection coupled with an enhanced safety profile makes these candidates ideal for potential use in livestock and humans.
Elsevier
